Trial Profile

EVALUATION OF THE TOLERANCE AND PHARMACOKINETIC PROFILE OF HIGH FAVIPIRAVIR DOSES IN HEALTHY VOLUNTEERS EVALUATION DE LA TOLERANCE ET DU PROFIL PHARMACOCINETIQUE DE DOSES ELEVEES DE FAVIPIRAVIR CHEZ LE VOLONTAIRE SAIN

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favipiravir (Primary)
Indications COVID 2019 infections; Ebola virus infections; Influenza virus infections; Severe fever with thrombocytopenia syndrome
Focus Adverse reactions
Acronyms FAVIDOSE

17 May 2024 Planned End Date changed from 1 Oct 2027 to 1 Nov 2027.
17 May 2024 Planned primary completion date changed from 1 May 2027 to 1 Jun 2027.
05 Apr 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com